Quantitative determination of platinum complexes in human plasma generated from the oral antitumour drug JM216 using directly coupled high-performance liquid chromatography-inductively coupled plasma mass spectrometry without desolvation

Abstract

A new method was developed and validated for measuring platinum species generated from the clinical antitumour agent JM216 in methanol extracts of human plasma using high-performance liquid chromatography-inductively coupled plasma mass spectrometry (HPLC-ICP-MS). Good separation of JM216 and three of its biotransformation products (JM118, JM518 and JM383) was achieved with a run time of 20 min using a C8 column (4.6×150 mm) and a gradient methanol-water mobile phase (pH 2.5) at a flow rate of 1 ml min^–1. The presence of methanol in the mobile phase and in the sample matrix suppressed the platinum counts and the gradient step was associated with some base-line drift. However, the quantitation of JM216 and its biotransformation products (JM118, JM518 and JM383) was achieved with good intra-assay precision (range 1-12% RSD), inter-assay precision (range 2.3-11% RSD), accuracy (range 89-103%) and limits of quantitation (range 1-2 ng ml^–1) without having to use a desolvation device. This new HPLC-ICP-MS technique has the advantages of greater sensitivity and efficiency compared to existing methods that use HPLC, fraction collection and the off-line detection of platinum by AAS.

References

1. A. H. Calvert, I. Judson and W. J. F. Van Der Vijgh, Cancer Surveys, 1993, 17, 189.
2. D. Peereboom, L. Wood, C. Connell, J. Spisak, D. Smith, D. Vaughn, C. Brassard, D. Lebwohl and R. Bukowski, Proc. Am. Soc. Clin. Oncol., 1998, 17, 314.
3. M. J. McKeage, F. Raynaud, J. Ward, C. Berry, D. O'Dell, L. R. Kelland, B. A. Murrer, P. Santabarbara, K. R. Harrap and I. R. Judson, J. Clin. Oncol., 1997, 15, 2691.
4. F. I. Raynaud, P. Mistry, A. Donaghue, G. Poon, L. R. Kelland, C. F. J. Barnard, B. Murrer and K. R. Harrap, Cancer Chemother. Pharmacol., 1996, 38, 155.
5. M. J. McKeage, P. Mistry, J. Ward, F. E. Boxall, S. Loh, C. O'Neill, P. Ellis, L. R. Kelland, S. E. Morgan, B. Murrer, P. Santabarbara, K. R. Harrap and I. R. Judson, Cancer Chemother. Pharmacol., 1995, 36, 451.
6. W. R. L. Cairns, L. Ebdon and S. J. Hill, Fresenius' J. Anal. Chem., 1996, 355, 202.
7. V. P. Shah, K. K. Midha, D. Dinge, I. J. McGilveray, J. P. Skelly, A. Yacobi, T. Layloff, C. T. Viswanathan, C. G. Cook, R. D. McDowall, K. A. Pittman and S. Spector, Eur. J. Drug Metab. Pharmacokinet., 1991, 16, 249.
8. Z. Zhao, K. Tepperman, J. G. Dorsey and R. C. Elder, J. Chromatogr., 1993, 615, 83.